Intravenous leiomyomatosis is a rare condition that has been described as being associated with venous occlusion by direct intravascular tumor extension, typically from a pelvic organ. We report an exceedingly rare case of intravenous leiomyomatosis extending into the inferior vena cava, leading to pulmonary embolism, hepatic venous outflow obstruction, and an acute Budd-Chiari syndrome. This is the second reported patient with intravenous leiomyomatosis with Budd-Chiari syndrome and, to our knowledge, the first reported patient who survived with surgery. Correlative images, illustrating computed tomography and magnetic resonance imaging findings characteristic of intravenous leiomyomatosis with secondary Budd-Chiari syndrome, are presented and discussed.
A normal cisterna chyli is a structure that may simulate retrocrural adenopathy on unenhanced CT. Our case report is significant because it highlights two cases in which patients with prior primary malignancies (medullary thyroid carcinoma, esophageal carcinoma) underwent PET-CT for re-staging, and in each case, a prominent right retrocrural structure is seen representing either a cisterna chyli or retrocrural metastasis. The physiologic activity of the structure on PET-CT is considered and cross-sectional abdominal images are examined in full as well. In both cases, the structure has a low attenuation on CT and a low SUVmax on PET-CT, consistent with a benign process. These cases demonstrate that with the combined use of CT attenuation and PET SUVmax as guiding parameters, a cisterna chyli should be more readily distinguishable from retrocrural adenopathy, and thus can help to avoid unnecessary invasive management of the patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.